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INTRODUCTION
The “resurrection” of the Sleeping Beauty (SB) transposon1 aroused 
the interest of the scientific community for its enormous potential 
as a tool in mammalian genome engineering studies. This interest 
conveyed in an extensive engineering effort aimed at ameliorating 
the transposition activity by modifying both components of the SB 
system, the transposon inverted repeats (IRs) and the transposase 
enzyme. These efforts resulted in the generation of the hyperactive 
SB100X transposase2 and T2 IRs arrangement modifying the outer 
and inner Direct repeats (DRs) sites and the spacer sequence between 
the DRs, showing a fourfold enhanced activity over the standard T 
IRs3 and the high-capacity “sandwich” IRs (SA),4 designed to trans-
pose large DNA fragment (>10 kb). The hyperactive SB100X coupled 
to the T2-based transposon has been already engaged in preclinical 
gene therapy applications,2,5–7 genome modification8–10 and, more 
recently, iPS reprogramming.11–13 Typically, the SB transposase is 
provided transiently by plasmid transfection to prevent remobiliza-
tion of the transposon integrated into the human genome,14 and 
its expression is usually driven by a strong constitutive promoter, 
e.g., the cytomegalovirus (CMV) promoter. Since overproduction 
inhibitory effects have been reported,15,16 a careful molar balance 
between the transposase and the transposon is required for opti-
mal transposition. However, despite the improved new methods 
of transfection, delivery of the two-component system remains a 
challenge for many applications. In particular, nonviral delivery 
methods are not suitable for primary cells such as keratinocytes, 
hepatocytes or photoreceptor cells that are refractory to transfec-
tion, thus developments of new delivery system gained increasing 
interests. Besides conventional transfection methods for plasmid 
and mRNA coding for transposase,17,18 viral delivery based on ade-
noviral,19,20 AAV,21 Baculovirus,22 gammaretroviral,23 and lentiviral24 
vectors has been proposed in the past. The use of integrating gam-
maretroviral and lentiviral vectors as vehicles for transposase deliv-
ery raise safety concerns due to the risk of uncontrollable rehopping 
of the transposon as a result of stable expression of the transposase. 
This can be circumvented by the use of shorter lived mRNA pack-
aged into retrovirus particles;23 or of integration-defective LVs car-
rying expressing SB11 transposase;25 or the hyperactive version 
SB100X.24 More recently, several in depth analyses about the rates 
on insertional mutagenesis and remobilization showed that they 
occurred infrequently.26
Alternatively, transcriptional regulation based on Tet-On system is 
widely used to control gene expression. The system, originally devel-
oped by Gossen and Bujard more than 20 years ago (1992), has under-
gone several refinements aimed to improve the efficacy limiting the 
leakiness of the transcription level in absence of the inducer. These 
modifications have included improvements of the Tet-responsive 
promoter obtained by substituting the minimal CMV promoter fused 
to the TetO7– element with the minimal promoter (-81) of the HSV-1 
timidine kinase (TK) gene 27 or by introducing a short (36 nt) spac-
ing between two consecutive TetO sites and increasing the number 
of TetO sites from 7 to 8.28 In 2000, a new transcriptional modulator, 
rtTA2S-M2, was generated by replacing the full-length VP16 transcrip-
tional activation domain by a full codon optimized domain derived 
from VP16 itself.29 This Tet-On variant was successfully used for ex vivo 
and in vivo delivery of tetracycline-regulated genes.30,31 In this study, 
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The Sleeping Beauty (SB) transposase and, in particular, its hyperactive variant SB100X raises increasing interest for gene therapy applica-
tion, including genome modification and, more recently, induced pluripotent stem cells (iPS) reprogramming. The documented cytotox-
icity of the transposase, when constitutively expressed by an integrating retroviral vector (iRV), has been circumvented by the transient 
delivery of SB100X using retroviral mRNA transfer. In this study, we developed an alternative, safe, and efficient transposase delivery sys-
tem based on a tetracycline-ON regulated expression cassette and the rtTA2S-M2 transactivator gene transiently delivered by integration-
defective lentiviral vectors (IDLVs). Compared with iRV-mediated delivery, expression of tetracycline-induced SB100X delivered by an 
IDLV results in more efficient integration of a GFP transposon and reduced toxicity. Tightly regulated expression and reactivation of the 
transposase was achieved in HeLa cells as wells as in human primary keratinocytes. Based on these properties, the regulated transposase-
IDLV vectors may represent a valuable tool for genetic engineering and therapeutic gene transfer.
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we took advantage of this new system to develop an efficient, safe, 
and transcriptionally regulated transposase delivery platform based 
on the Tet-On regulatory system and on integration-defective lenti-
viral vector (IDLV). We generated two IDLV vectors, one carrying the 
rtTA2S-M2 transactivator and the second bearing the tightly regu-
lated, drug-inducible SB100X expression cassette. The combination 
of the two vectors resulted in a strong reduction of background 
expression in the off-state and in a high induction of transposase 
expression upon doxycycline (dox) treatment. Before addressing the 
transposition of a GFP expression cassette, we examined the poten-
tial cytotoxic side-effects of the Tet-regulated SB100X carried by an 
IDLV in comparison to the constitutively expressed SB100X delivered 
by a gammaretroviral vector (iRVSB) or by lentiviral vector (IDLVSB). 
We showed that dox-induced or constitutively expressed SB100X 
expression in IDLV did not affect cell proliferation, and did not trig-
ger DNA damage response or apoptosis, in contrast to iRVSB, which 
induces a G2/M arrest and apoptotic cell death even in the absence 
of a cotransfected transposable element. Comparing the IDLV trans-
posase delivery platform with the iRVSB vector, we found that expres-
sion of dox-induced or constitutively expressed SB100X delivered by 
IDLVs gave rise to more efficient integration of a sandwich GFP trans-
poson (pSAGFP)4,32 in HeLa cells in absence of selection. We showed 
significant regulation of SB100X expression upon dox treatment in 
human primary keratinocytes resulting in a transposition of the GFP 
reporter gene in keratinocytes cultivated in vitro on 3T3 feeder layer.
Thus, the dox-induced transposase IDLV platform that combines 
the efficiency and the transcriptional regulation of SB100X repre-
sents a promising application in human primary cells.
ReSUlTS
Transcriptional regulation of the hyperactive SB transposase
To overcome the cytotoxic effects of the constitutive expression of 
the SB100X delivered by an integration competent retroviral vector, 
we developed two alternative constructs, in which the expression 
of the transposase was controlled by a tetracycline-inducible activa-
tion system. The pTetOCMVSB and pTetOTKSB plasmids contained 
the SB100X expression cassette under the control of the CMV imme-
diate-early minimal promoter (-53) or the minimal promoter (-81) of 
the HSV-1 gene TK linked to the bacterial Tet operator (TetO). The tet-
racycline controlled reverse transcriptional activator (rtTA2S-M2)29 was 
expressed under the control of the phosphoglycerate kinase (PGK) 
promoter (Figure 1). In the presence of the inducer, the tetracycline 
analogue dox, the rtTA2S-M2 protein allows activation of TetO-CMV 
or TetO-TK transcription. The control CMVSB plasmid contained 
the transposase expression cassette driven by the CMV promoter/
enhancer (Figure 1).
Regulated expression of the transposase and transposition of a 
sandwich transposon carrying a PGK-driven GFP cassette (pSAGFP)32 
(Figure 1) were assessed by cotransfecting HeLa cells with pSAGFP 
and pCMVSB or pSAGFP and pTetOTKSB or pTetOCMVSB alone and 
in combination with pPGKrtTA2S-M2 in the presence and absence of 
dox. As control, HeLa cells were transfected with the pSAGFP alone. 
Half of the cells were harvested 48 hours after transfection, and 
their mRNA analyzed for SB100X expression by real time qRT-PCR. 
The increased transposase expression in the activating conditions 
(plus rtTA2S-M2 and ± dox) was measured over the background 
(pTetOTKSB and pTetOCMVSB alone). As shown in Figure 2a,b pro-
nounced activation (16 fold in presence of dox) of transposase 
expression was achieved in the cells co-transfected with pTetOTKSB 
and pPGKrtTA2S-M2 plasmids compared to the cells that received 
only pTetOTKSB. A robust activation (71 fold in presence of dox) but 
more leaky SB100X expression (sevenfold in absence of dox) was 
measured in the cells cotransfected with the pTetOCMVSB and the 
pPGKrtTA2S-M2 compared with the cells in absence of the activa-
tor. The cells were kept in culture to perform a transposition experi-
ment aimed at the identification of integration efficiency of the IR 
flanked transgene without any selective pressure. At least three 
independent experiments for each regulated transposase were per-
formed in order to reduce variability due to transfection procedure. 
We determined also by qPCR the copy number of transposon and 
transposase plasmids in HeLa cells 2 days post-transfection (see 
Supplementary Figure S1). The copy number of GFP transposon 
was pretty comparable among the TetOTK and TetOCMV cotrans-
fected samples; whereas SB100X copy number in pCMVSB sample 
was lower than all the other SB-transfected samples nevertheless it 
showed a high SB100X expression (see Supplementary Figure S2).
Transgene expression during the culture period (up to 20 days) 
was measured by FACS to determine the percentage of GFP+ cells 
that, at the endpoint of culture, harbored at least one copy of 
transposon expressing GFP per cell (see Supplementary Figure S3). 
Figure 2b shows on the Y-axis the %GFP+ cells 20 dpt / %GFP+ cells 
2 dpt × 100 for each sample. The percentage corresponding to the 
pSAGFP sample alone (on average of 0.7%) was subtracted to the 
percentage deriving from SB-treated sample. The TetO-TK promoter 
resulted in a ratio of GFP+ cells of 56% with respect to the TetO-CMV 
promoter (78%) even in absence of the activator. A mild induction 
upon dox addition (63%) was detected with the TetOTKSB plas-
mid compared with 10% measured with the TetO-CMV regulated 
transposase in presence of dox, probably due to overproduction 
Figure 1  Schematic outline of the plasmids and viruses carrying 
transposon or transposase. pCMVSB carries the SB100X transposase 
coding sequence placed under the control of the cytomegalovirus (CMV) 
promoter. The sandwich GFP transposon (pSAGFP) carries the GFP under 
phosphoglycerate kinase (PGK) promoter embedded in SA transposon. 
The plasmids pTetOTKSB and pTetOCMVSB carry the transposase under the 
Tet operator (TetO) and the minimal TK (mTK) or minimal CMV promoter 
(mCMV), respectively. The plasmid pPGKrtTA2S-M2 codes for the rtTA2s-M2 
transactivator transcribed from PGK promoter. Black arrows represent the 
transposon IRs. All the IDLV vectors (IDLVTKSB, IDLVSB, and IDLVrtTA2S-M2) 
were obtained by cloning the transposase and transactivator expression 
cassettes described above into nonintegrating lentiviral vector. Lastly the 
IDLVT2 vector carries the GFP reporter gene driven by the PGK promoter 
embedded in T2 transposon. All the expression cassettes carry the SV40 
poly-Adenylation signal (not shown). The constructs are not in scale. PGK, 
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inhibition (Figure 2b). These data clearly indicate the superior regu-
latory property of the TetO-TK promoter and the fateful effect of reg-
ulation of the transposase activated by TetO-CMV promoter, there-
fore the TetO-TK configuration was chosen to regulate the SB100X 
transposase. A more controlled delivery of the two Tet-components 
could allow a fine regulation of transposase expression avoiding 
overproduction inhibition and toxicity.
Nonintegrating lentiviral-based transposase activity.
In order to get transposition in primary cells that are refractory to 
physicochemical transfection, i.e., keratinocytes, we incorporated 
the transposase into integration-defective lentiviral vector (IDLV). 
To overcome cytotoxic effects of constitutive expression of the 
transposase carried by IDLV that could persist in the genome of the 
target cells due to residual integration activity, we developed two 
IDLVs expressing the TetO-TK regulated transposase (IDLVTKSB) and 
the reverse transactivator rtTA2S-M2 (IDLVrtTA2S-M2) (Figure 1). We 
also introduced the 900 bp Woodchuck Hepatitis Virus post-tran-
scriptional regulatory element (WPRE)33 at the 3′ end of the SB100X 
cDNA to possibly increase mRNA processing and stability. IDLV 
particles pseudotyped with the Vesicular Stomatitis Virus glycopro-
tein (VSV-G) were packaged, concentrated and measured by HIV-1 
Gag p24 immunocapture. To determine the most efficient vectors 
dose combination, we performed a dose escalation experiment 
Figure 2 Sleeping Beauty (SB) transposase expression and activity from Tet-On transcriptionally regulated plasmids. (a) Quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR) assay on the transposase expression. HeLa cells were transfected with pTetOTKSB and pTetOCMVSB 
alone or in combination with pPGKrtTA2S-M2 in presence and in absence of dox. Transposase expression was measured by Taqman RT PCR and plotted 
as RQ value with respect to the off state (pTetOTKSB and pTetOCMVSB alone, RQ value = 1). The experiment was performed in triplicate and is presented 
as mean value ± standard error of the mean (SEM). Dashed lines connect samples showing significant different values (*P < 0.1, **P < 0.05). (b) HeLa cells 
were cotransfected with the transposase coding plasmids described above and the pSAGFP transposon. As positive control a constitutive expression 
of the transposase provided by the pCMVSB plasmid was used. The experiment was performed in triplicate and on the Y-axis is presented %GFP+ cells 
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transducing HeLa cells with increasing doses (130, 260, and 2,600 ng 
p24) of IDLVTKSB in combination with IDLVrtTA2S-M2 (960 and 
9,600 ng p24), in presence and in absence of dox. Nice activation of 
the transposase was measured in all conditions (see Supplementary 
Figure S4) although higher dose of IDLVTKSB was required to obtain 
approximately eightfold activation of SB100X expression over the 
background, as shown in the qRT-PCR analysis (IDLVTKSB alone) 
(Figure 3a). To easily compare the qRT-PCR data on SB100X expres-
sion obtained with plasmid with those from viruses, we merged the 
data in Supplementary Figure S2.
For some gene therapy purposes, iPS reprogramming or gener-
ation of cell lines stably and highly expressing the gene of interest, 
a fast clearance of transposase or multiple transposition events 
are desired. Cellular reprogramming based on SB system repre-
sents a novel, viable and safe approach of generating iPS cells.11 
Grabundzija et al. clearly showed the presence of iPS cell colonies 
3 days post-transposase’s delivery, indicating that the activity of 
SB100X was carried out and its expression would no longer be 
required. Thus a transcriptional silencing of transposase expres-
sion, that could follow a different timing in different cell,34 could 
be desired and benefit the iPS colonies formation and growth. The 
generation of stable cell line for viral production could require 
more than one copy of the packaging genes. To increase the copy 
number and the expression of the packaging genes, multiple 
rounds of transposon/transposase delivery could be required. 
Thereby drug-inducible reactivation of the transposase provided 
in the first round will limit the readministration of the two-compo-
nents system to the transposon plasmid.
Thus, we asked whether the transcriptionally controlled SB100X, 
expressed by the combination of two IDLVs, could fulfil the quick 
down-regulation of transposase expression upon dox withdrawal 
and its reactivation upon dox treatment, so that multiple transduc-
tion cycles that could exhaust primary cells limiting their clonogenic 
potential, e. g., keratinocytes, are avoided.
We followed the switching of the on and off-state of transposase 
expression by semi-quantitative RT-PCR assay on mRNA purified 
from transduced HeLa cells. The transposase expression over time, 
at the indicated time points, was calculated upon GAPDH normal-
ization and plotted as SB100X mRNA fold change respect to highest 
transposase expression level (value = 1) achieved 48 hours post-
transduction upon dox treatment (Figure 3b). We transduced HeLa 
cells with IDLVTKSB (2,600 ng p24) and IDLVrtTA2S-M2 (9,600 ng 
p24) in absence and in presence of dox (black and light gray line, 
respectively). Two days post-transduction we extracted the mRNA 
to perform the RT-PCR and we split the bulk activated by dox for 
48 hours in two sub-populations, in the bulk A (light gray line) we 
readministered the dox whereas in the other bulk the dox was not 
added (bulk B) (dashed line). Five days post-transduction, in the 
bulk A, kept constantly in presence of dox, SB100X expression is 
clearly detected compatible with the dilution of the IDLVTKSB vec-
tor in actively replicating HeLa cells. Conversely, we observed an 
almost complete shut off of transposase expression 3 days post dox 
withdrawal, 5 days post-transfection (5 dpt) in the bulk B (dashed 
line). Interestingly, the SB100X expression was rescued 2 days after 
the readministration of dox for 48 hours (7 dpt) (dotted line) in the 
bulk B, reaching at day 9, a level comparable to the permanently 
activated SB100X expression (light gray line) (bulk A). RT-PCR assay 
performed 12 and 20 dpt on the reactivated and the permanent 
activated sub-populations respectively, showed no SB100X expres-
sion, consistently with the almost undetectable IDLVTKSB vector in 
the HeLa genome (see Supplementary Figure S5).
We also evaluated the integration of a GFP transposon mediated 
by the regulated SB100X in comparison to a constitutively expressed 
SB100X carried by IDLV (IDLVSB) (Figure 1) and by a gamma retro-
viral vector (iRVSB).23 HeLa cells were transfected with the pSAGFP 
transposon and 16 hours later were transduced with IDLVrtTA2S-M2 
(9,600 ng p24) and IDLVTKSB (260 and 2,600 ng p24 doses) vec-
tors in presence and in absence of dox and with the constitutively 
SB100X expressing vectors, IDLVSB and iRVSB. We evaluated the 
copy number of pSAGFP transposon and SB transposase by qPCR 2 
days post-transfection/transduction (see Supplementary Figure S6). 
The copy number of the SB transposase carried by dox-regulated 
IDLV vector was related, not surprisingly, to the amount of IDLVTKSB 
virus delivered (260 ng or 2,600 ng p24) to the cells, however the 
copy number in the samples ± dox was comparable. The SB100X 
copy number in iRVSB-treated sample is lower than all other SB vec-
tors in particular the IDLVTKSB (2,600 ng p24)+IDLVrtTA2M2-treated 
sample although they sustained comparable transposition of GFP 
cassette delivered with comparable efficiency (see Supplementary 
Figure S7). The activity of iRVSB is presumably ascribed to the robust 
SB100X expression measured by qRT-PCR (see Supplementary 
Figure S2). Expression of the GFP was traced every 6 days for a total 
of 21 days (see Supplementary Figure S7). The %GFP+ cells 21 dpt 
/ %GFP+ cells 2 dpt ×100 was 78% with the high dose of regulated 
SB vector compared with 58% and 76% scored with the iRVSB and 
IDLVSB vector respectively. Low dose of the IDLVTKSB in combina-
tion with IDLVrtTA2S-M2 vector reached 42% upon dox activation. 
As performed for the cotransfection experiment in Figure 2b, the 
%GFP+ cells 21 dpt / %GFP+ cells 2 dpt ×100 for each sample was nor-
malized to the transposon alone (on average of 0.58%) (Figure 3c). 
Interestingly, this condition resulted in fivefold increase of GFP+ cells 
in the ON state and in poor (9%) transposase activity when the dox 
is not added to the cell culture.
Transcriptionally regulated transposase delivered by IDLV is not 
cytotoxic
To investigate whether Tet-regulated transposase could affect cell 
proliferation, we performed a Crystal Violet (CV) assay on HeLa cells 
transduced with high doses of IDLVTKSB and IDLVrtTA2S-M2 vec-
tors and with the constitutively SB100X expressing vectors, iRVSB 
and IDLVSB. As control we generated an IDLVNC and iRVNC vectors 
carrying a PGK-GFP expression cassette. Analyzing the absorbance 
(A540 nm) 48, 72, 96, and 120 hours post-transduction in all sample 
treated, we observed a modest but not significant decrease in 
cell proliferation following dox-induced SB100X expression in the 
sample cotransduced with IDLVTKSB-IDLVrtTA2S-M2 respect to the 
IDLVNC, particularly at 120 hours post-transduction. At the above 
time point, the comparison between cells transduced with iRVNC 
and IDLVs vectors, and between IDLVSB and IDLVNC, did not show 
significant differences in cell growth. Differently, iRVSB caused an 
evident and irreversible inhibition of cell growth, already marked at 
72 hours post-transduction (Figure 4a).
Propidium-Iodide (PI) monoparametric cell cycle analysis was 
then performed by flow cytometer at 72 hours post-transduction 
(Figure 4b). No differences were detected in the distribution of 
cell populations throughout the different phases of the cell cycle 
following activation of SB100X expression (compare IDLVTKSB- 
IDLVrtTA2S-M2 vs. IDLVTKSB- IDLVrtTA2S-M2+dox). Same behavior 
was observed in the IDLVSB transduced cells. In contrast, iRVSB 
transduction accumulated the cells in the G2/M phase (from 21% of 
iRVNC to 53% of iRVSB cells), to the detriment of G0/G1 population, 
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Figure 3 Transcriptionally regulation and transposition mediated by Sleeping Beauty (SB) transposase carried by IDLV vectors. (a) qRT-PCR assay 
on HeLa cells transduced with IDLVTKSB (2,600 ng p24) in presence or in absence of IDLVrtTA2S-M2 (9,600 ng p24) and dox. Transposase expression 
upon activation was measured by real time Taqman RT-PCR and plotted as RQ value with respect to the off state (IDLVTKSB alone, RQ value = 1). 
The experiment was performed in triplicate and is presented the mean ± SEM. Dashed lines connect samples showing significant different values 
(***P< 0.005) (b) On and off state of the transposase expression. A time course experiment (2, 5, 7, 9, 12, and 20 days post-transduction, dpt) was 
performed in HeLa cells cotransduced with the IDLVTKSB (2,600 ng p24) and IDLVrtTA2S-M2 (9,600 ng p24). Light gray and black lines represent cells 
cultivated in presence and in absence of dox, respectively. Dashed line represents the effect of dox withdrawal up to 20 dpt. Dotted line shows the 
effect of readministration of dox 7 dpt. (c) HeLa cells were transfected with the pSAGFP transposon and transduced with the IDLVTKSB (260 ng p24 
and 2,600 ng p24; gray and black bars respectively) and IDLVrtTA2SM2 (9,600 ng p24) in presence and in absence of dox and compared with the iRVSB 
(dotted bar) and IDLVSB (light gray bar) vectors. The experiment was performed in triplicate and on the Y-axis is presented the %GFP+ cells 21 dpt / 
%GFP+ cells 2 dpt ×100 (mean ± SEM). Dashed lines connect samples showing significant different values (*P < 0.1, **P < 0.05). qRT-PCR, quantitative 
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as already described by Galla et al. 23 and the percentage of SubG1 
cells raised from 2.5% (iRVNC) to 18% (iRVSB).
Although no increase of SubG1 events was detected by PI flow 
cytometer analysis in IDLVrtTA2S-M2 cells, we further investigated 
whether dox-induced SB100X could activate an apoptotic response. 
The Annexin-V assay, which detects externalized phosphatidylserine 
(PS) at the plasma membrane, was used to evaluate early apoptosis 
(Figure 4c). The percentage of Annexin-V positive cells detected fol-
lowing time-course incubation of IDLVTKSB- IDLVrtTA2S-M2 with 
dox was comparable with control cells (IDLVTKSB- IDLVrtTA2S-M2). 
Differently, constitutive SB100X expression by gammaretroviral vec-
tor (iRVSB) showed an evident increase of Annexin-V staining for all 
the time points analyzed. Conversely IDLVSB vector behaves simi-
larly to the IDLVNC control.
Figure 4 Effects of transcriptionally regulated expression of Sleeping Beauty (SB) transposase on cell viability and proliferation. (a) Proliferation rates 
of HeLa cells transduced with the indicated vectors by absorbance measurement (A540nm) of crystal violet staining at 48, 72, 96, and 120 hours post-
transduction (hpt). (b) Distribution of transduced cells (% cells) throughout the different phases of the cell cycle at 72 hours post-transduction, as 
measured by PI-cytometer analysis of DNA content. (c) Percentages of cells positive to AnnexinV staining at the indicated time points (hpt). The 
experiments in panel a, b, c were performed in triplicate and are presented as mean ± SEM. (d) Western blot analysis of CCNB1, p53, H2AX-S139P 
and cleaved-PARP1 expression in total extracts from IDLVTKSB+IDLVrtTA2S-M2 +dox, iRVSB and IDLVNC transduced cells at the indicated time points. 
Adriamycin (Adr) was used as positive control for DNA damage and apoptosis activation. Signals were normalized with a polyclonal antibody against 
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Finally, we analyzed by Western Blot the expression of key pro-
teins involved in cell cycle progression and apoptotic response. As 
shown in Figure 4d, the levels of CyclinB1 (CCNB1), which controls 
the G2 to M progression, were not affected by dox-induced SB100X 
expression, while an increase was observed in iRVSB transduced 
cells, consistent with the accumulation G2/M events (Figure 3b). 
Compared with control cells, the expression of the tumor suppres-
sor p53, regulator of cell proliferation and apoptosis, rose at 72 hours 
post-transduction in IDLVTKSB-IDLVrtTA2S-M2+dox cells, and then 
decreased to control levels at 120 hours, hinting at a reversible acti-
vation of p53 induced by dox treatment. Differently, constitutive 
SB100X expression led to a long-term increase of p53, presumably 
involved in cell cycle arrest and cell death mechanisms. To corrobo-
rate that Tet-regulated SB100X did not activate DNA damage and 
apoptosis, in opposition to iRVSB, we analyzed the expression of 
γH2AX-S139P, H2AX histone variant phosphorylated at Ser139 in 
response to DNA damage, and cleaved-PARP1, hallmark of apopto-
sis. As expected, their expression levels were increased by iRVSB, but 
no changes were observed following dox-induced SB100X activa-
tion, compared with IDLVNC.
Overall, these data demonstrate that Tet-regulated transposase 
expression has no cytotoxic effects and could therefore be used to 
mediate transposition in human primary cells.
Transcriptional regulation of SB transposase in human primary cells
The efficacy of the regulated transposase coupled to its nontoxic 
effect prompted us to investigate its activity in human primary 
keratinocytes. We firstly evaluated the transcriptional response to 
dox treatment. We cotransduced human primary keratinocytes with 
IDLVTKSB and IDLVrtTA2S-M2 in the presence and absence of dox 
and as control with IDLVSB. The qRT-PCR analysis on transposase 
expression 5 dpt showed a 15-fold transcriptional activation over 
the uninduced cells and a level of SB100X expression comparable 
to the IDLVSB vector where transposase is driven by the constitutive 
CMV promoter (Figure 5a).
To perform transposition experiments, human primary kerati-
nocytes were co-transduced with IDLVT2 alone or in combination 
with IDLVTKSB+IDLVrtTA2S-M2 in presence or absence of dox or 
with IDLVSB and kept in culture on irradiated 3T3 feeder layer for 
5 days, without selective pressure. Transgene expression was mea-
sured by flow cytometer analysis to determine the percentage of 
GFP+ cells 2 days post-transduction and at the endpoint of culture 
(5 days), when the transposon alone drops to barely undetectable 
level (on average of 0.6%) (see Supplementary Figure S8a). The 
ratios between the percentage of GFP+ cells at the endpoint and 
the percentage of GFP+ cells 2 days post-transduction, normal-
ized to the transposon alone, is shown in Figure 5b. To investigate 
whether Tet-regulated transposase vector could affect cell viability, 
1.6 × 105 keratinocytes transduced with IDLVT2 in combination with 
IDLVTKSB and IDLVrtTA2S-M2 or with IDLVSB were counted 2 days 
post-transduction. We observed a reduction on keratinocytes viabil-
ity in the samples transduced with 3 IDLV vectors (IDLVT2, IDLVTKSB, 
and IDLVrtTA2M2) respect to IDLVT2 ± IDLVSB-transduced cells 
48 hours post-transduction (see Supplementary Figure S8b), prob-
ably related to the total viral load since after day 2 all the samples 
underwent comparable cell growth (data not shown). To improve 
the system, we incorporated the TetOTK-regulated SB100X in the 
rtTA2S-M2 transactivator vector generating the IDLVTKreg vec-
tor (see Supplementary Figure S9a). Firstly we assessed the tran-
scriptional activation of the all-in-one vector (IDLVTKreg) upon 
dox treatment. We transduced human primary keratinocytes with 
IDLVTKreg, IDLVTKSB+IDLVrtTA2S-M2 in the presence and absence 
of dox. The qRT-PCR analysis on SB100X expression 5 dpt showed a 
10-fold transcriptional activation of the IDLVTKreg vector over the 
uninduced cells (IDLVTKreg -dox) (see Supplementary Figure S9b). 
Then, we assessed the transposition of Tet-regulated IDLV vectors 
in human primary cells. Primary keratinocytes were co-transduced 
with IDLVT2 alone or in combination with IDLVTKreg in presence or 
absence of dox and kept in culture on irradiated 3T3 feeder layer for 
5 days, without selective pressure. Unfortunately the residual level 
of GFP+ cells in the IDLVTKreg+IDLVT2-treated samples, either in 
presence or in absence of dox, was below 1% and comparable with 
the IDLVT2-treated sample (data not shown). These results indicate 
Figure 5 Transcriptionally regulation and Sleeping Beauty (SB)-mediated 
transposition in human primary keratinocytes. (a) qRT-PCR assay on 
primary keratinocytes transduced with IDLVTKSB and IDLVrtTA2S-M2 
in presence or in absence of dox compared to the IDLVSB. (b) Primary 
keratinocytes were cotransduced with the IDLVT2 transposon, IDLVs 
transposase vectors in absence and in presence of dox. The experiment 
was performed in duplicate and on the Y-axis is presented the %GFP+ 
cells 5dpt / %GFP+ cells 2 dpt ×100 (mean ± SEM). Dashed lines connect 
samples showing significant different values (**P < 0.05). qRT-PCR, 
quantitative reverse-transcriptase polymerase chain reaction; IDLV, 
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that the all-in-one vector did not ameliorate the integration of GFP 
transposon in this experimental setting. In summary, our findings 
demonstrated that the hyperactive SB transposase packaged into 
IDLV particles is transcriptionally regulated, nontoxic, and possess 
gene transfer potential in human primary cells as needed for poten-
tial gene therapy applications.
DISCUSSION
This study presents an efficient, transcriptionally regulated and 
nontoxic IDLV platform for the delivery of Sleeping Beauty trans-
posase and transposon. Although the SB system1 was resurrected to 
provide a nonviral method for introducing defined DNA sequences 
into vertebrate chromosomes, an efficient delivery of the integra-
tion machinery is mandatory to achieve long lasting transgene 
expression in cycling target cells, as recently shown by the success-
ful use of integrating lentiviral vectors in clinical applications.35–38 
More recently, the SB system was applied to the engineering of 
T-cells with a chimeric antigen receptor (CAR) in order to redirect 
T-cell specificity.39,40 In this specific context, nucleofection technique 
was used to deliver the transposase SB11 plasmid and the transpo-
son plasmid carrying a CD19-specific CAR to the T-cells.41 To extend 
the use of the SB system to hardly transfectable primary cells (e. g., 
keratinocytes and photoreceptor cells) and evaluate its perfor-
mance in many settings, it is crucial to expand the range of cellular 
delivery tools for the SB components. In the last years, examples of 
incorporation of the SB components into viral vectors to take advan-
tage of the viral cell entry properties are numerous.20,21,24,25 None of 
them, however, addressed the issue of the controlled expression of 
the transposase into the target cells. For some gene therapy appli-
cations, such as iPS reprogramming or generation of SB-mediated 
genetic modification, a quick clearance of transposase or its guided 
reactivation to get multiple transposition events is desired.
This study introduces the Tet-On-mediated transcriptional regula-
tion of transposase provided by a combined IDLVs platform. We gen-
erated two IDLV vectors, one carrying the SB100X transposase under 
the minimal TetO-TK promoter and the second carrying the reverse 
transactivator rtTA2S-M2 under the constitutive PGK promoter. We 
were able to improve the regulatory performance by replacing the 
minimal CMV with the minimal TK promoter and by fine tuning the 
transposase activation over the background expression in the off 
state by an appropriate vector dose combination. Coupled to a tight 
regulation of the SB100X transposase, we reported the possibility 
to switch on and off its expression during time, up to the dilution 
of the nonintegrating IDLV vectors during cell division. As shown 
in Figure  3b, 7 days post-transduction, readministration of dox in 
the IDLVs cotransduced bulk population triggered transposase 
expression to a level compared with that observed in the cells con-
tinuously kept in the presence of dox. Although we used the high 
 transposase vector dose (2,600 ng p24), a complete clearance of 
SB100X expression was obtained 3 days after dox withdrawal or 20 
dpt in the continuously dox-treated sample due to complete dilution 
of the IDLV episomes. The dynamic range and Tet-regulation could 
be important in iPS reprogramming where a fast down-regulation 
of SB100X expression is desired to avoid uncontrolled mobilization 
of the reprogramming transposon vector. Conversely, the possibil-
ity of reactivating the residual transposase episomes later on could 
be really appreciated during the generation of a stable cell line, i.e., 
packaging cells for viral vectors or cell line stably expressing a gene 
of interest. In these cases, multiple transposition events are required 
and readministration of only one component, the transposon, is pre-
ferred particularly when a viral delivery is chosen.
We evaluated the transposition rate of the regulated-IDLVs plat-
form compared with the iRVSB and IDLVSB vector. Transposition of 
the SAGFP cassette from a plasmid substrate results in higher fre-
quency of genomic integration when Tet-regulated transposase 
system is provided. Not surprisingly, we observed that the efficiency 
of transgene insertion into the genome due to SB transposase-
mediated integration was vector dose-dependent. High dose of 
IDLV vectors in presence of dox resulted in high mRNA expression, 
thus in high number of cells that integrate at least one transposon 
(78%). In contrast, lower IDLVs doses led to remarkably lower back-
ground of transposase expression in the off state and a relevant 
induction of transposition in presence of the drug.
However, the correlation between transposase expression 
and number of cells that integrated at least one copy of trans-
poson is not linear, in particular in HeLa cells transfected with 
pTetOCMVSB+pPGKrtTA2-M2 in presence of dox and in cells trans-
duced with iRVSB, where overproduction inhibition coupled to 
cytotoxicity may limit the transposition rate.
The cytotoxic effects of the Tet-regulated transposase system 
were investigated by comparing the high doses-IDLVs platform with 
an integration competent retroviral vector carrying the constitu-
tively expressed SB100X. As previously reported,23 the iRVSB showed 
heavy apoptotic effects on a bulk population of transduced HeLa 
cells, while IDLV-regulated transposase expression did not affect 
cell viability. The modest decrease of the proliferation rate observed 
in IDLVTKSB-IDLVrtTA2S-M2 cotransduced cells in presence of dox 
compared with its control (IDLVTKSB-IDLVrtTA2S-M2 w/o dox) could 
be ascribed to dox administration to the cells. Indeed, it has been 
shown that dox at the concentration of 1 μg/ml can reduce cell 
proliferation of multiple human cell lines, included HeLa cells.42 
The transient increase in the expression of p53, a tumor suppres-
sor involved both in cell cycle arrest and in apoptosis mechanisms, 
could be one of the causes of the observed delay in cell growth. 
Despite this slight decrease in the proliferation rate, we did not 
observe neither an increase in apoptotic cells following dox nor an 
accumulation of cells in a specific phase of the cell cycle. Therefore, 
we conclude that dox-induced transposase expression from an IDLV 
does not lead to pronounced cytotoxic effects, an important differ-
ence compared with stable expression from an integrated retroviral 
vector.
To test the Tet-regulated IDLVs platform in human primary 
keratinocytes, we transduced the cells with the IDLVTKSB and 
IDLVrtTA2S-M2 vectors and scored the activation of the transposase 
expression upon dox. We observed a clear dox-dependent activa-
tion of the transposase demonstrating the possibility to employ 
this IDLVs platform in primary cells. Unfortunately the all-in-one 
vector (IDLVTKreg) weakly responded to dox treatment probably 
due to not correct balance between rtTA2S-M2 activator and TetOTK 
responsive element, thereby did not sufficiently support the trans-
position of GFP expression cassette in primary keratinocytes. In pri-
mary cells cotransduced with IDLVTKSB, IDLVrtTA2S-M2, and IDLVT2 
vectors the %GFP+ cells 5dpt / %GFP+ cells 2 dpt x ×100 was 12% 
and had some impact on keratinocytes viability probably due to 
the total viral load. Noteworthy, the transduction efficiency of the 
IDLVT2 vector was ∼2.5-fold lower than transfection efficiency of 
pSAGFP transposon in HeLa cells. Moreover, we believed that the 
conformation of transposon template provided by IDLV vector may 
limit the overall transposition efficiency.24,43 Probably circularization 
of the transposon template, coupled to the regulated transposase 
system, could increase transposition rate, thus taken into consider-
ation for future applications.
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MATeRIAlS AND MeTHODS
Plasmids
The pTetOCMVSB plasmid was generated by cloning the TetOminhCMV 
promoter (from pUHC13.3)44 upstream the SB100X coding sequence 
inserted in the pBlueScript vector (pBS-SB100X). The pTetOTKSB plasmid 
was obtained by cloning the TetOminTKpromoter27 upstream the SB100X 
coding sequence (pBS-SB100X). The pSAGFP was described in Turchiano 
et al.32 The pCCL-PGKrtTA2S-M2 was kindly provided by Prof. Zappavigna, 
University of Modena and Reggio Emilia, Italy (IDLVrtTA2S-M2). The expres-
sion cassette pPGKrtTA2S-M2 derived from pCCL-PGKrtTA2S-M2 plasmid. 
The pCCL-TetOTKSB (IDLVTKSB) was achieved by cloning the TetOminTKSB 
sequence into a pCCL.LV vector. Similarly, was cloned the pCCL-CMVSB100X 
(IDLVSB). The pCCLT2GFP plasmid (IDLVT2) was generated in two steps: 
as first the PGKGFPSV40polyA was cloned, according to vector designed 
shown in Vink et al.25 between the T2 IR of the pT2/BH plasmid provided 
by Prof. Zoltan Ivics (Paul Ehrlich Institute, Langen, Germany), the result-
ing plasmid was then inserted into a pCCL.LV vector. The pCCLTKSBreg 
plasmid was achieved by cloning TetOminTKSB in the pCCL-PGKrtTA2S-M2 
(IDLVTKreg). The pCMVSB100X was kindly provided by Prof. Zoltan Ivics, 
Paul Ehrlich Institute, Langen Germany.
Cell culture and viral production
HeLa and HEK293T cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum, 100 units/ml penicillin 
and 100 mg/ml streptomycin (Lonza Ltd, Basel Switzerland). Swiss mouse 
3T3-J2 cells (a kind gift from Yan Barrandon, EPFL, Lausanne) were grown 
in Dulbecco’s modified Eagle’s medium supplemented with 10% donor 
bovine serum (GIBCO, Thermo Fisher Scientific, Monza Italy), 50 IU/ml 
penicillin–streptomycin, and 4 mmol/l glutamine. Primary human keratino-
cytes from foreskin biopsy were plated onto lethally irradiated 3T3-J2 cells 
and cultured in keratinocyte growth cFAD medium, a Dulbecco’s modified 
Eagle’s medium and Ham’s F12 media mixture (3:1) containing fetal bovine 
serum (10%), penicillin–streptomycin (1%), glutamine (2%), insulin (5 μg/
ml), adenine (0.18 mmol/l), hydrocortisone (0.4 μg/ml), cholera toxin (0.1 
nmol/l), and triiodothyronine (2 nmol/l). After 3 days, EGF at a concentra-
tion of 10 ng/ml was added to the culture (KC medium). Keratinocytes were 
trypsinized at subconfluency and replated onto a new feeder layer.
Viral stocks pseudotyped with the vesicular stomatitis virus G protein were 
prepared by transient cotransfection of HEK293T-cells with transfer vector, 
pMD.Lg/pRRE.D64VInt packaging plasmid, pMD2.VSV-G envelope–encoding 
plasmid, and pRSV-Rev.45 Vector particles were concentrated by ultracentri-
fugation and titrated by HIV-1 Gag p24 immunocapture (Perkin Elmer Life 
Sciences, Milan, Italy). Titres of IDLVTKSB, IDLVPGKrtTA2-M2, and IDLVT2 vec-
tors are the following respectively: 259 ng/µl p24, 960 ng/µl p24, and 916 ng/µl 
p24. The titration of IDLVTKreg was based on a dose-escalating (10, 30, 50, and 
100 µl) experiment in order to get higher SB activation upon dox treatment and 
lower toxic effects on the primary keratinocytes. Thus, we used 100 µl to trans-
duce primary keratinocytes. For gammaretroviral vector production (iRVSB), 
pRSF91SB100X transfer plasmid23 was cotransfected with MLV-gag-pol33 and 
pMD.G plasmids. Vector particles were concentrated by ultracentrifugation.
Transfections and transduction of HeLa cells and primary human 
keratinocytes
Transfection of HeLa cells. 2.5 × 105 HeLa were transfected with FugeneHD 
transfection reagent (Roche, S.p.A. Milan, Italy). Each transfection reaction 
containing 2 μg of DNA was combined with 6 μl of FugeneHD and subse-
quently mixed by pulse-vortexing for a few seconds. The mixes were there-
after left at room temperature for 10 minutes in order to allow the forma-
tion of lipoplexes. After the 10 minutes had expired, each mix was added 
drop-by-drop to a cell culture sample, which was subsequently incubated 
at 37°C. The transposon/transposase amounts of plasmid DNA were calcu-
lated to respect the stoichiometric ratio of 2:1 in a total quantity of 2 μg. 1 
μg of transposon-only plasmid mixed to 1 μg of carrier DNA was used for 
nontransposed control.
Transduction of HeLa cells. LV or RV transduction was performed by spin-
oculation at 754×g for 45′ in the presence of polybrene (8 μg/ml). After 6 
hours at 37°C, the retro or lenti vectors were replaced with regular medium 
in presence and in absence of 1 μmol/l dox. The percentage of GFP+ cells 
was determined 2 days and 15–20 days post-transfection/transduction via 
flow cytometer, then we plotted the %GFP+ cells 20 dpt/%GFP+ cells 2 dpt 
×100 for each sample. The percentage corresponding to the pSAGFP sam-
ple was subtracted to the SB-treated sample. In the transposition experi-
ments, HeLa cells were transfected with 2 μg of pSAGFP transposon using 
FugeneHD reagent and 16 hours later, cells were transduced wit SB-coding 
viral vectors. HeLa cells transfected only with the transposon plasmid rep-
resented the control for transposition experiments.
Transduction of primary human keratinocytes. 1.6 × 105 keratinocytes 
were LV-transduced in the cFAD medium in the presence of polybrene 
(8 μg/ml). Amounts of IDLVTKSB, IDLVPGKrtTA2-M2, and IDLVT2 vec-
tors used to transduce primary keratinocytes are the following, respec-
tively: 13,000 ng of p24, 48,000 ng of p24, and 9,160 ng of p24. Then the 
keratinocytes+vector+polybrene were plated onto lethally irradiated 3T3-
J2 cells at 25°C for 30 minutes, subsequently the cells were shifted to 37°C. 
After 6 hours a 37°C we added cFAD medium to the culture in the presence 
and in the absence of 1 μmol/l dox. The next day the cFAD medium was re-
placed with KC medium. Transduced keratinocytes were grown to subcon-
fluency or confluence, trypsinized and replated onto new feeder-layers for 
future analysis. The percentage of transduced-transposed cells was deter-
mined 2–5 days post-transduction via flow cytometer. To discriminate the 
keratinocytes from the 3T3J2 feeder layer we used the monoclonal Anti-
Feeder (APC) antibody mouse conjugated (Miltenyi Biotech S.r.l, Bologna, 
Italy) according to protocol.
Western blot analysis
In this analysis, 105 HeLa cells were transduced with LV and RV vectors 
at different multiplicity of infection. 72 hours, 96 hours, and 120 hours 
post-transduction cells were harvested, washed twice with phosphate-
buffered saline and cells lysates were obtained by using Laemmli buf-
fer (Tris-HCL 20 mmol/l pH7.5, ethylene Diamine Tetraacetic Acid 
(EDTA) 3 mmol/l, Glycerol 20%, sodium dodecyl sulphate (SDS) 2% and 
β-Mercaptoethanol 5%). Total protein extracts (20 μg) were separated by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (NUPAGE 
4–12% BT GEL 1.0 MM12W, Life Technologies, Monza), transferred to 
nitrocellulose membranes and probed with mouse monoclonal anti-
H2A.X-S139P (cat. 16–193 Merck S.p.A. Milano, Italy), mouse monoclo-
nal anti-CyclinB1 (cat. V152 GeneTex, Irvine, CA), mouse monoclonal 
anti-p53 (cat. sc-126 Santa Cruz Biotechnology, Heidelberg, Germany), 
mouse monoclonal anti PARP1 (cat. sc-8007 Santa Cruz Biotechnology, 
Heidelberg, Germany) and antivinculin (cat. V9131, Sigma Aldrich) in Tris-
buffered saline with 0.05% Tween (Sigma Aldrich, Milan, Italy) and 5% 
milk powder (Regilait, Saint Martin Belle Roche France).
Semiquantitative RT PCR and real time qRT-PCR analysis
Total RNA from the HeLa and keratinocytes transfected/transduced cells was 
isolated with the RNeasy Mini kit plus (Qiagen, Hilden, Germany), according 
to the manufacturer’s protocol. cDNA was synthesized in a 20 µl reaction 
using 100 ng total RNA and SuperScript III (Life Technologies).
Semiquantitative reverse-transcriptase polymerase chain reaction 
(RT-PCR) analysis was performed with the following oligonucleotides.
SB for: 5′-GCCACTCAGCAAGGAAGAAG-3′,





PCR cycles: 94°C 30 seconds, 58°C 30 seconds, 72°C 30 seconds.
Real time qRT-PCR was performed as following. Total RNA was isolated from 
HeLa cells, with the RNeasy Plus Mini Kit (Qiagen). The RNA was reverse 
transcribed with random primers with the Superscript III reverse tran-
scriptase (Life Technologies). The Real Time Taqman PCR was performed in 
96-well plates on the ABI Prism 7900 Sequence Detection System (Applied 
Biosystems Thermo Fisher Scientific, Milan, Italy) with TaqMan Universal 
PCR Master Mix and Assays-On-Demand (Applied Biosystems), with a final 
reaction of 25 μl. The PCR primers and 6-carboxyfluorescein (FAM) probe 
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased 
from Applied Biosystems. The SB100X transposase levels were measured 
using custom primers forward SB.2 for 5′-GAAGAAGCCACTGCTCCAAAA-3′, 
reverse primers SB.2 rev 5′-CCCCATGTGCAGTTGCAA-3′ and probe SB FAM: 
CATAAGAAAGCCAGACTACGG. All samples were performed in triplicate. 
The relative expression (RQ value) of the target genes was normalized to 
the level of GAPDH in the same cDNA by the 2-ΔΔCT quantification.
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Quantification of transposon and transposase copies by real-time 
Taqman PCR (qPCR)
For the quantification of the transposon and transposase copies in trans-
fected/transduced cells, qPCR with the primer pairs specific for GFP (Assay 
ID Mr04097229_mr, Applied Biosystem) and SB100X (SB.2 forward, reverse, 
and SB probe described above) were performed.
The quantitative PCR (qPCR) was performed in 96-well plates on the ABI Prism 
7900 Sequence Detection System (Applied Biosystems) with TaqMan Universal 
PCR Master Mix and Assays-On-Demand (Applied Biosystems), with a final reac-
tion of 25 μl. To normalize the different samples, the same amount of genomic 
DNA was analyzed by qPCR detecting the GAPDH (Assay ID Hs03929097_g1). As 
positive control and for the calculation of standard curves, eight serial dilutions 
of the plasmid standard pCMVSB and pSAGFP (containing 109–102 plasmid cop-
ies per 5 μl) were prepared and subjected to qPCR analysis in triplicate.46
Cell proliferation and apoptosis analysis
The inhibition of proliferation was measured by Crystal Violet staining, and 
the concentration at which cellular growth is inhibited by 50% (IC50) was 
determined following the indicated time points post transduction.47 Briefly, 
the cell monolayer was fixed with methanol and stained with 0.05% Crystal 
Violet solution in 20% methanol for 1 hour. After washes, cells were allowed 
to dry. The incorporated dye was solubilized in acidic isopropanol and 
determined by absorbance measurement (A540nm). The extracted dye was 
proportional to cell number. Cells were harvested Propidium-Iodide (PI) and 
Annexin V staining were performed at 48 , 72, 96, and 120 hours after trans-
duction by an FACS CANTO cytometer (BD Biosciences, Milan, Italy).
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